Reduction of painful area as new possible therapeutic target in post-herpetic neuropathic pain treated with 5% lidocaine medicated plaster: A case series

Roberto Casale, Maria Di Matteo, Cristina E. Minella, Guido Fanelli, Massimo Allegri

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Post-herpetic neuralgia (PHN) is neuropathic pain persisting after an acute episode of herpes zoster, and is associated with severe pain and sensory abnormalities that adversely affect the patient's quality of life and increase health care costs. Up to 83% of patients with PHN describe localized neuropathic pain, defined as "a type of neuropathic pain characterized by consistent and circumscribed area(s) of maximum pain". Topical treatments have been suggested as a first-line treatment for localized neuropathic pain. Use of 5% lidocaine medicated plaster could reduce abnormal nervous peripheral discharge and via the plaster could have a "protective" function in the affected area. It has been suggested that use of this plaster could reduce pain as well as the size of the painful area. To evaluate this possible outcome, we retrospectively reviewed eight patients with PHN, treated using 5% lidocaine medicated plaster. During a follow-up period of 3 months, we observed good pain relief, which was associated with a 46% reduction in size of the painful area after one month (from 236.38±140.34 cm2 to 128.80±95.7 cm2) and a 66% reduction after 3 months (81.38±59.19 cm2). Our study cohort was composed mainly of elderly patients taking multiple drugs to treat comorbidities, who have a high risk of drug-drug interactions. Such patients benefit greatly from topical treatment of PHN. Our observations confirm the effectiveness of lidocaine plasters in the treatment of PHN, indicating that 5% lidocaine medicated plaster could reduce the size of the painful area. This last observation has to be confirmed and the mechanisms clarified in appropriate larger randomized controlled trials.

Original languageEnglish
Pages (from-to)353-357
Number of pages5
JournalJournal of Pain Research
Volume7
DOIs
Publication statusPublished - Jun 23 2014

Fingerprint

Neuralgia
Lidocaine
Pain
Therapeutics
Herpes Zoster
Drug Interactions
Pharmaceutical Preparations
Health Care Costs
Comorbidity
Cohort Studies
Randomized Controlled Trials
Quality of Life
Observation

Keywords

  • Chronic pain
  • Drug-drug interactions
  • Localized neuropathic pain
  • Patient's outcome
  • Topical treatment

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Reduction of painful area as new possible therapeutic target in post-herpetic neuropathic pain treated with 5% lidocaine medicated plaster : A case series. / Casale, Roberto; Di Matteo, Maria; Minella, Cristina E.; Fanelli, Guido; Allegri, Massimo.

In: Journal of Pain Research, Vol. 7, 23.06.2014, p. 353-357.

Research output: Contribution to journalArticle

Casale, Roberto ; Di Matteo, Maria ; Minella, Cristina E. ; Fanelli, Guido ; Allegri, Massimo. / Reduction of painful area as new possible therapeutic target in post-herpetic neuropathic pain treated with 5% lidocaine medicated plaster : A case series. In: Journal of Pain Research. 2014 ; Vol. 7. pp. 353-357.
@article{cd9db62d31274ab3bf209fb71d24ee6f,
title = "Reduction of painful area as new possible therapeutic target in post-herpetic neuropathic pain treated with 5{\%} lidocaine medicated plaster: A case series",
abstract = "Post-herpetic neuralgia (PHN) is neuropathic pain persisting after an acute episode of herpes zoster, and is associated with severe pain and sensory abnormalities that adversely affect the patient's quality of life and increase health care costs. Up to 83{\%} of patients with PHN describe localized neuropathic pain, defined as {"}a type of neuropathic pain characterized by consistent and circumscribed area(s) of maximum pain{"}. Topical treatments have been suggested as a first-line treatment for localized neuropathic pain. Use of 5{\%} lidocaine medicated plaster could reduce abnormal nervous peripheral discharge and via the plaster could have a {"}protective{"} function in the affected area. It has been suggested that use of this plaster could reduce pain as well as the size of the painful area. To evaluate this possible outcome, we retrospectively reviewed eight patients with PHN, treated using 5{\%} lidocaine medicated plaster. During a follow-up period of 3 months, we observed good pain relief, which was associated with a 46{\%} reduction in size of the painful area after one month (from 236.38±140.34 cm2 to 128.80±95.7 cm2) and a 66{\%} reduction after 3 months (81.38±59.19 cm2). Our study cohort was composed mainly of elderly patients taking multiple drugs to treat comorbidities, who have a high risk of drug-drug interactions. Such patients benefit greatly from topical treatment of PHN. Our observations confirm the effectiveness of lidocaine plasters in the treatment of PHN, indicating that 5{\%} lidocaine medicated plaster could reduce the size of the painful area. This last observation has to be confirmed and the mechanisms clarified in appropriate larger randomized controlled trials.",
keywords = "Chronic pain, Drug-drug interactions, Localized neuropathic pain, Patient's outcome, Topical treatment",
author = "Roberto Casale and {Di Matteo}, Maria and Minella, {Cristina E.} and Guido Fanelli and Massimo Allegri",
year = "2014",
month = "6",
day = "23",
doi = "10.2147/JPR.S65398",
language = "English",
volume = "7",
pages = "353--357",
journal = "Journal of Pain Research",
issn = "1178-7090",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Reduction of painful area as new possible therapeutic target in post-herpetic neuropathic pain treated with 5% lidocaine medicated plaster

T2 - A case series

AU - Casale, Roberto

AU - Di Matteo, Maria

AU - Minella, Cristina E.

AU - Fanelli, Guido

AU - Allegri, Massimo

PY - 2014/6/23

Y1 - 2014/6/23

N2 - Post-herpetic neuralgia (PHN) is neuropathic pain persisting after an acute episode of herpes zoster, and is associated with severe pain and sensory abnormalities that adversely affect the patient's quality of life and increase health care costs. Up to 83% of patients with PHN describe localized neuropathic pain, defined as "a type of neuropathic pain characterized by consistent and circumscribed area(s) of maximum pain". Topical treatments have been suggested as a first-line treatment for localized neuropathic pain. Use of 5% lidocaine medicated plaster could reduce abnormal nervous peripheral discharge and via the plaster could have a "protective" function in the affected area. It has been suggested that use of this plaster could reduce pain as well as the size of the painful area. To evaluate this possible outcome, we retrospectively reviewed eight patients with PHN, treated using 5% lidocaine medicated plaster. During a follow-up period of 3 months, we observed good pain relief, which was associated with a 46% reduction in size of the painful area after one month (from 236.38±140.34 cm2 to 128.80±95.7 cm2) and a 66% reduction after 3 months (81.38±59.19 cm2). Our study cohort was composed mainly of elderly patients taking multiple drugs to treat comorbidities, who have a high risk of drug-drug interactions. Such patients benefit greatly from topical treatment of PHN. Our observations confirm the effectiveness of lidocaine plasters in the treatment of PHN, indicating that 5% lidocaine medicated plaster could reduce the size of the painful area. This last observation has to be confirmed and the mechanisms clarified in appropriate larger randomized controlled trials.

AB - Post-herpetic neuralgia (PHN) is neuropathic pain persisting after an acute episode of herpes zoster, and is associated with severe pain and sensory abnormalities that adversely affect the patient's quality of life and increase health care costs. Up to 83% of patients with PHN describe localized neuropathic pain, defined as "a type of neuropathic pain characterized by consistent and circumscribed area(s) of maximum pain". Topical treatments have been suggested as a first-line treatment for localized neuropathic pain. Use of 5% lidocaine medicated plaster could reduce abnormal nervous peripheral discharge and via the plaster could have a "protective" function in the affected area. It has been suggested that use of this plaster could reduce pain as well as the size of the painful area. To evaluate this possible outcome, we retrospectively reviewed eight patients with PHN, treated using 5% lidocaine medicated plaster. During a follow-up period of 3 months, we observed good pain relief, which was associated with a 46% reduction in size of the painful area after one month (from 236.38±140.34 cm2 to 128.80±95.7 cm2) and a 66% reduction after 3 months (81.38±59.19 cm2). Our study cohort was composed mainly of elderly patients taking multiple drugs to treat comorbidities, who have a high risk of drug-drug interactions. Such patients benefit greatly from topical treatment of PHN. Our observations confirm the effectiveness of lidocaine plasters in the treatment of PHN, indicating that 5% lidocaine medicated plaster could reduce the size of the painful area. This last observation has to be confirmed and the mechanisms clarified in appropriate larger randomized controlled trials.

KW - Chronic pain

KW - Drug-drug interactions

KW - Localized neuropathic pain

KW - Patient's outcome

KW - Topical treatment

UR - http://www.scopus.com/inward/record.url?scp=84903317116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903317116&partnerID=8YFLogxK

U2 - 10.2147/JPR.S65398

DO - 10.2147/JPR.S65398

M3 - Article

AN - SCOPUS:84903317116

VL - 7

SP - 353

EP - 357

JO - Journal of Pain Research

JF - Journal of Pain Research

SN - 1178-7090

ER -